Cell Therapeutics Inc.

Christina Waters, Ph.D. joined CTI's management team in October 2008. Dr. Waters holds a Ph.D. in Genetics from the University of California, Davis and a M.B.A. from UCLA's Anderson School of Management. Dr. Waters has been involved in biotechnology research since 1988 and has recently served as the Director of Scientific Development at the Genomics Institute of the Novartis Research Foundation an institute that is focused on applying integrated state-of-the-art technologies in chemistry, biology, automation, and information sciences in order to pursue new approaches towards the understanding of complex biomedical problems in cancer biology, immunology, neuroscience, and metabolic as well as infectious diseases. Most recently she was President and COO of A Tyr Pharma, a company involved in the development of protein therapeutics across a broad range of diseases.

Jack W. Singer, M.D., is a founder and Director of CTI and was appointed Chief Medical Officer in January 2004. Dr. Singer was formerly Executive Vice President, Research Program Chair. As Chief Medical Officer, Dr. Singer is the primary thought leader for CTI clinical and medical strategy. He is a noted expert in hematologic cancers, having developed the clonal theory of leukemia. He has authored more than 240 peer-reviewed manuscripts and 13 chapters in textbooks on cell biology and clinical drug development and holds 14 patents. He has been an invited speaker at numerous medical conferences, including, the 6th International Symposium on Polymer Therapeutics, and he is a member of the Society for Clinical Investigation. Prior to joining CTI, Dr. Singer was Professor of Medicine at the University of Washington and full Member of the Fred Hutchinson Cancer Research Center. From 1975 to 1992, he was the Chief of Medical Oncology at the Veterans Administration Medical Center in Seattle. In addition, Singer served as an advisor to the National Cancer Institute and was a consultant to several pharmaceutical companies prior to joining CTI.

Louis A. Bianco is a founder of CTI and has been CTI's Executive Vice President, Finance and Administration since February 1, 1992, and a Director of CTI from the Company's inception in September 1991 to April 1992, and from April 1993 to April 1995. From January 1989 through January 1992, Mr. Bianco was a Vice President at Deutsche Bank Capital Corporation in charge of risk management. Mr. Bianco is a Certified Public Accountant and received his M.B.A. from New York University.

Dan Eramian joined CTI as Executive Vice President, Corporate Communications in March 2006. Eramian will serve as a member of the Company's senior management team and will be responsible for developing and implementing the internal and external communications strategy. Eramian brings nearly 13 years of experience in the biotechnology industry to the position. Most recently Eramian was Vice President of Communications at BIO, a Washington, DC-based industry organization representing more than 1,200 biotechnology companies, academic institutions, state biotechnology centers, and related organizations. Prior to BIO, Eramian was Assistant Administrator of Communications at the Small Business Administration and Director of Public Affairs at the Department of Justice and Chief Spokesman for the Attorney General. Previously, Eramian served as Chief of Staff to the Senate Leader in the Massachusetts Legislature, and was also Executive Editor of Suburban World Newspapers in the Boston area. He holds a B.A. in English Literature from UMass/Amherst and an M.P.A. from Suffolk University.

Array

Mark Levonyak joined CTI in 2000 as the Western Sales Director responsible for developing and leading the National Sales Force and Medical Affairs teams to promote and educate oncologists and hematologists on the benefits of TRISENOX, CTI's first commercial product designed for the treatment of acute promyelocytic leukemia. In 2001 Mr. Levonyak was promoted to Director, Oncology & Hematology Marketing and was instrumental in guiding the expansion of the CTI Marketing department as it relates to product management, new product planning, market development, and market analytics. He transformed brand strategies into tactical programs to ensure optimal positioning and awareness of the CTI product portfolio. In early 2004 Mark was promoted to Vice President, Oncology & Hematology Marketing and was given the added responsibility to lead the XYOTAX Global Core team. He is responsible for the development and integration of business and strategic plans for the CTI product portfolio with a emphasis on pre-launch activities for XYOTAX in the treatment of NSCLC. The 15 years prior to joining CTI, Mr. Levonyak worked in numerous commercial roles at SmithKline Beecham Pharmaceuticals. From 1995 to 2000 he worked as the Oncology Commercial Director, where he developed and led the sales, medical affairs, and medical education teams in the Western Area. Mr. Levonyak played a critical role in the creation of the oncology business unit at SKB. From 1985 to 1995 Mr. Levonyak was promoted into many different commercial roles ranging from District Sales Manager, National Accounts Manager, Sales Trainer, Recruiter, and Sales Representative. He consistently received leadership and performance awards for his accomplishments. Mr. Levonyak's received his BA in Biological Sciences and Chemistry from California State University system.

Dr. Stromatt has served as our Senior Vice President and Chief Medical Officer since August 2008. Prior to joining Trubion, Dr. Stromatt held several senior management positions at Cell Therapeutics, most recently serving as Executive Vice President, Clinical Development and Regulatory Affairs. Prior to Cell Therapeutics, Dr. Stromatt was an employee of Northwest Biotherapeutics Inc., where he held the position of Vice President of Clinical Research and Chief Medical Officer. His earlier positions included: Senior Vice President at CE Unterberg Tobin, an investment bank, consultant to a variety of biotechnology and pharmaceutical firms, Vice President of Clinical Research at Synergen, and Director of Medical Affairs at Searle Pharmaceuticals. Dr. Stromatt received an M.D. from the University of Chicago and an MBA and B.A. from the University of Colorado.

Mauro G. Premi was named Acting Managing Director and Board Member of CTE in September 2006, leading the Bresso Senior Management Team. He also serves as Finance and Accounting Director for CTE, his position since joining the Company in April 2006. Before joining CTE, Mr. Premi covered interim Finance Director positions for special projects at Varta (Rayovac Group), Cooper Cameron, and CMGRP (IPG Group). Mr. Premi gained a strong background in finance, controlling, and general management functions while covering various managerial positions in multinational companies, including Pall Corp. and Demag (former Mannesmann Group, later Siemens). With the latter company and its Italian subsidiaries, Mr. Premi spent more than 10 years working in Germany, and was promoted to the position of Group Finance and Controlling Director in Italy. He had full responsibility for finance (Italian, German and US GAAP), planning and controlling, as well as general administration. He was directly responsible at different times for various special operations such as start-up, acquisitions, and selling of companies and/or operative branches. Mr. Premi, graduated in Business Administration from L. Bocconi University, Milano, Italy and has taken business management courses in the UK, Germany, and the US.

Gabriella Pezzoni, Ph.D. was named Scientific Director of CTE in September 2006 with responsibility for preclinical research and development. She was a founding member of the Italian pharmaceutical company Novuspharma with responsibility as Director of Biology prior to its merger with CTI. Before joining Novuspharma, Dr. Pezzoni was head of oncology research at Boehringer Mannheim Italia SpA., where she was responsible for New Drug Applications and Investigational New Drug applications. Before joining Boehringer Mannheim Italia she worked at Farmitalia Carlo Erba Research Centre in Nerviano, Milano (ex Pfizer Inc.) coordinating in vivo anti-tumor activity studies. Dr. Pezzoni has also worked at the Tumour Institute in Milan and holds a degree in biological sciences from the University of Pavia.

Giovanni Ravaioli joined CTE in November 2004 as Human Resources Director. In this position, he is responsible for managing all HR-related activities supporting the Company's strategic plans and corporate policies. Mr. Ravaioli has more than 16 years experience as HR Manager and Director in national and international pharmaceutical companies, including Italfarmaco, Zilliken, Lifepharma, Dade Behring, and Quintiles. His focus has been on personnel development, organizational development, and mergers and acquisitions. He also has several years experience in recruitment, training and development, and industrial relations. Mr. Ravaioli started his career as a Regulatory Affairs Specialist at an Italian pharmaceutical company after earning his Animal Science Degree at the University of Milan (Italy).

Phillip M. Nudelman, Ph.D., has been a director of CTI since March 1994 and Board Chairman since 2005. Dr. Nudelman served as President and CEO of Group Health Cooperative, the nation's largest consumer owned health care system, and as chairman and president of Kaiser/Group Health. He retired in January 2000 as CEO Emeritus. In April 2000 Dr. Nudelman was named President and CEO of the Hope Heart Institute, Seattle's leading nonprofit cardiovascular research and education center. A noted leader in improving healthcare in the country, Nudelman has served on the White House Task Force for Health Care Reform and the President's Advisory Commission on Consumer Protection and Quality in Health Care. He has served on the Pew Health Professions Commission and on the American Medical Association's Task Force on Ethics, the Woodstock Ethics Commission, and as chairman of the American Association of Health Plans. Dr. Nudelman has served as a director on several corporate boards including Spacelabs Medical, Inc., Personalpath Systems, Inc., Advanced Technology Ultrasound, First Medic, Cytran, and Franklin Health. He currently serves on the boards of CTI (chairman), Optistor, and Zynchros.

Erich Platzer, M.D., joined CTI's Board as Director in early 2004 upon the merger of CTI and Novuspharma. He formerly served as chairman of the board at Novuspharma. Prior to this he was head of global oncology marketing for Roche, where he was involved in the launch of rituximab (Mabthera) and trastuzumab (Herceptin). Dr. Platzer holds a degree from the University of Erlangen, Germany, where he later became associate professor of medicine.

Dr. Telling has been one of our directors since December 2006. Prior to his retirement in 2007, Dr. Telling was a corporate officer of Pfizer, most recently as Vice President of Corporate Policy and Strategic Management since 1994. He joined Pfizer in 1977 and was responsible for strategic planning and policy development throughout the majority of his career. He currently serves on the board of directors of Eisai N.A., Medex, and Aequus. Dr. Telling is also a member of the Committee for Economic Development, IBM s Healthcare & Life Sciences Advisory Council, the March of Dimes National Foundation Board, ORBIS, the EAA, and the United Hospital Fund. Dr. Telling received his BA from Hamilton College and his Masters of Industrial and Labor Relations and Ph.D. in Economics and Public Policy from Cornell University.

Dr. Mundinger has been as a director of the Company since 2002 and chairwoman of the Clinical Quality Committee of the Board since 2003. She is the centennial professor in health policy at the Columbia University School of Nursing and, since 1986, has served as dean of Columbia's School of Nursing. Dr. Mundinger is an elected member of the Institute of Medicine of the National Academies, the American Academy of Nursing and the New York Academy of Medicine. She is a director of Cell Therapeutics Inc. and UnitedHealth Group Incorporated.

Dick's career spans 38 years with more than 24 years of leadership roles in the oncology focused biosciences. He is presently the Managing Director of TGen Accelerators, LLC. He started two biopharmaceutical companies, Triton Biosciences Inc. and ILEX Oncology Inc. (ILXO) and served as CEO in both companies for periods of 8 years each. In addition, Dick has served in executive positions at not-for-profit organizations, including the Cancer Therapy and Research Center (CTRC), The San Antonio Technology Accelerator Initiative (SATAI) and the Translational Genomics Research Institute (TGen). Dick joined TGen in January 2003 as its Chief Operating Officer. At Triton and ILEX, Dick led teams that were responsible for the clinical development of multiple important therapeutic products; four or which are currently in the practice of medicine: Betaseron for patients with multiple sclerosis; Fludara and CAMPATH , both for patients with chronic lymphocytic leukemia; and, Clolar for acute lymphocytic leukemia. In 2004 ILEX was acquired by Genzyme Corporation in a stock for stock transaction valued at approximately $1.0 billion. Dick also serves on the Boards of Directors of Parexel International (PRXL) and Xilas Medical.